Document:

Exhibit 4.1

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES

EXCHANGE ACT OF 1934

 

General

 

We are currently authorized
to issue up to 1,500,000,000 shares of Common Stock, and 50,000,000 shares of preferred stock, par value $0.0001 per share, of
which none were issued and outstanding as of the date of this Annual Report. All of our issued and outstanding shares have been
validly issued, fully paid and non-assessable.

 

Our bylaws permit the board
of directors to issue the whole or any part of any unissued balance of the authorized capital stock. Our certificate of incorporation
permits us to increase or decrease the number of authorized shares of Common Stock by the affirmative vote of the holders of a
majority of the stock of the Company entitled to vote.

 

Common Stock

 

Voting Rights

 

Holders of our Common Stock
are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our Common Stock
have no cumulative voting rights. Further, holders of our Common Stock have no preemptive, conversion, redemption or subscription
rights and there are no sinking fund provisions applicable to our Common Stock.

 

Liquidation Rights

 

In the event of our liquidation,
dissolution or winding-up, holders of our Common Stock have the right under Section 281 of the Delaware General Corporation Law
to a ratable portion of assets remaining after satisfaction in full of the prior rights of our creditors, all liabilities and the
total liquidation preferences of any outstanding shares of preferred stock.

 

Dividends

 

Subject to preferences
that may be applicable to any outstanding shares of preferred stock, holders of our Common Stock are entitled to receive dividends,
if any, as may be declared from time to time by our board of directors, or board, out of our assets which are legally available.

 

Preferred Stock

 

Our Certificate of Incorporation
authorizes 50,000,000 shares of preferred stock, par value $0.0001 per share, of which none were issued and outstanding as of the
date of this registration statement. The board of directors is authorized to provide for the issuance of these unissued shares
of preferred stock in one or more series, and to fix the number of shares and to determine the rights, preferences and privileges
thereof. Accordingly, the board of directors may issue preferred stock which may convert into large numbers of shares of Common
Stock and consequently lead to further dilution of other shareholders.

 

On November 22, 2020,
certain stockholders representing more than 50% of our outstanding share capital approved the elimination of the our entire authorized
class of fifty million (50,000,000) undesignated preferred stock, thereby reducing the total number of shares of capital stock
that we may issue from one billion five hundred fifty-thousand (1,550,000,000) shares to one billion five hundred thousand (1,500,000,000)
shares, all of which are designated as common stock (the “Certificate of Elimination”). The Certificate of Elimination
will be effective upon the filing with the Secretary of the State of Delaware, which was not completed as of the date of this
annual report’s filing.

 

Warrants and Options

 

Warrants:
On June 12, 2020, the Company issued to Citrine S A L , WealthStone Private Equity Ltd, WealthStone Holdings Ltd, Golden Holdings
Neto Ltd, Beezz Home Technologies Ltd, Citrine Biotech 5 LP, Citrine High Tech 6 LP, Citrine High Tech 7 LP, Citrine 8 LP, Citrine
9 LP and Citrine Biotech 10 LP, 5,589,172 A warrants and 5,589,172 B warrants to purchase a total of 11,178,344 shares of
Common Stock of the Company. Each of the A warrants and B warrants has an exercise price of $0.10 per share.

 

Options:
As of December 31, 2020, the Company had 46,762 stock options issuable under our 2017 Employee Incentive Plan.

 

    	 

    	 

    

 

Convertible Promissory Notes

 

In the last three years,
we issued convertible promissory notes in an aggregate principal amount of $1,170,000 in a series of convertible loan agreements.

 

Anti-Takeover Provisions

 

The provisions of Delaware
law, our Certificate of Incorporation and our Bylaws may have the effect of delaying, deferring or discouraging another person
from acquiring control of the Company. These provisions, which are summarized below, may have the effect of discouraging takeover
bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board
of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or
unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals
could result in an improvement of their terms.

 

Amended and Restated Certificate of Incorporation
and Amended and Restated Bylaw Provisions

 

Our amended and restated
certificate of incorporation and our amended and restated bylaws include a number of provisions that could deter hostile takeovers
or delay or prevent changes in control of our management team, including the following:

 

	●	Board of directors’ vacancies. Our Certificate of Incorporation provides that vacancies on the board of directors may be filled only by the affirmative vote of a majority of the directors then in office, irrespective of whether there is a quorum, or by a sole remaining director. Additionally, the number of directors to serve on our board of directors is fixed solely and exclusively by resolution duly adopted by our board of directors. This would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.
	 	 
	●	Special meetings of stockholders. Our Certificate of Incorporation currently provides that special meetings of our stockholders may be called by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons.
	 	 
	●	No cumulative voting. The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation’s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation does not provide for cumulative voting.
	 	 
	●	Amendment of charter provisions. Any amendment of our Certificate of Incorporation requires the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class. Amendments to the Bylaws may be executed pursuant to a resolution by the board of directors pursuant to an affirmative vote of a majority of the directors then in office, or by the affirmative vote of at least 75% of the outstanding shares of capital stock entitled to vote.

 

	●	Issuance of undesignated preferred stock. Our board of directors has the authority, without further action by the stockholders, to issue up to 50,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock, which may be converted into large numbers of shares of Common Stock, would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means.

 

    	 

    	 

    

 

	●	Delaware Business Combination Statute. The Company is subject to the “business combination” provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date such person becomes an interested stockholder, unless the business combination or the transaction in which such person becomes an interested stockholder is approved in a prescribed manner. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an “interested stockholder” is a person that, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, and the anti-takeover effect includes discouraging attempts that might result in a premium over the market price for the shares of our Common Stock.
	 	 
	●	Exclusive forum. Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or (iv) any action asserting a claim against us governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees.

 

Transfer Agent and Registrar

 

The transfer agent and
registrar for our Common Stock is Worldwide Stock Transfer, LLC, with a mailing address of One University Plaza, Suite
505, Hackensack, NJ 07601, and a facsimile number of (201) 820-2010,

 

Listing

 

Our Common Stock is quoted
on the OTCQB under the symbol “CTGL.” We have applied to list our Common Stock on the Nasdaq Capital Market. No assurance
can be given that our application will be approved or that a trading market will develop.Exhibit 10.9

 

April
12, 2021

 

Citrine Global, Corp.

 

Board of Directors

 

	 	Re:	Second Amendment to Convertible Note Purchase Agreement dated April 1, 2020

 

Reference is made to that
certain Convertible Note Purchase Agreement, dated April 1, 2020, entered by and among Citrine Global, Corp. (the “Company”),
Citrine S A L Investment & Holdings Ltd, WealthStone Private Equity Ltd, WealthStone Holdings Ltd, Golden Holdings Neto Ltd,
Beezz Home Technologies Ltd, Citrine Biotech 5 LP, Citrine High Tech 6 LP, Citrine High Tech 7 LP, Citrine 8 LP, Citrine 9 LP and
Citrine Biotech 10 LP (collectively, the “Buyers”), and as further amended on June 12, 2020. The purpose of
this amendment letter (the “Amendment Letter”) is to amend and modify the CL Agreement.

 

The Company and the Buyers
hereby agree to amend and modify the CL Agreement as follows:

 

		1.	The
                                            annual interest on the convertible promissory notes, attached thereto as Exhibit A to the
                                            CL Agreement (the “Notes”), should be changed, effective January 1, 2021,
                                            to nine percent (9%) per annum.
	 	 	 
		2.	In
                                            the event of an investment of at least $5 million of the Company’s securities is consummated
                                            by the Company, then the Company shall repay the principal amount and annual interest of
                                            the Notes out from those proceeds.
	 	 	 
		3.	The
                                            Exercise Price of the A Warrant and the B Warrant should each be $0.10 per share, and the
                                            terms of each of the A Warrant and B Warrant should be extended by one (1) year.

 

This Amendment Letter shall
become effective as of the date hereof. There are no conditions precedent or subsequent to the effectiveness of this Amendment
Letter. Except as modified by the terms of this Amendment Letter, the terms and provisions of the CL Agreement shall remain unmodified
and in full force and effect. Other than as stated herein, this Amendment Letter shall not operate as a waiver of any condition
or obligation imposed on the parties under the CL Agreement. In the event of any conflict, inconsistency, or incongruity between
any provision of this Amendment Letter and any provision of the CL Agreement, the provisions of this Amendment Letter shall govern
and control. This Amendment shall not be changed or modified orally, but only by an instrument in writing signed by the parties.

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the undersigned Buyers and Company have caused this Second Amendment to the CL Agreement to be duly executed as of the date first
above written.

  

	Name: __________________	 	Name: _____________________
	 	 	 
	Signature: ______________________	 	Signature: ____________________
	 	 	 
	for and on behalf of:	 	for and on behalf of:
	 	 	 
	CITRINE GLOBAL, CORP.	 	CITRINE S A L INVESTMENT & HOLDINGS LTD

 

	Name: ________________________	 	Name: __________________
	 	 	 
	Signature: ______________________	 	Signature: _______________
	 	 	 
	for and on behalf of:	 	for and on behalf of:
	 	 	 
	BEEZZ HOME TECHNOLOGIES LTD	 	WEALTHSTONE PRIVATE EQUITY LTD

 

	Name: ____________________	 	Name: __________________
	 	 	 
	Signature: ______________________	 	Signature: _______________
	 	 	 
	for and on behalf of:	 	for and on behalf of:
	 	 	 
	WEALTHSTONE HOLDINGS LTD	 	GOLDEN HOLDINGS NETO LTD

 

	Name: ____________________	 	Name: __________________
	 	 	 
	Signature: ______________________	 	Signature: _______________
	 	 	 
	for and on behalf of:	 	for and on behalf of:
	 	 	 
	CITRINE BIOTECH 5 LP	 	CITRINE HIGH TECH 6 LP

 

	Name: __________________	 	Name: __________________
	 	 	 
	Signature: ______________________	 	Signature: _______________
	 	 	 
	for and on behalf of:	 	for and on behalf of:
	 	 	 
	CITRINE HIGH TECH 7 LP	 	CITRINE 8 LP

 

	
     Name: ____________________
	 	
     Name: ________________

	 	 	 
	Signature: ______________________	 	Signature: _______________
	 	 	 
	for and on behalf of:	 	for and on behalf of:
	 	 	 
	CITRINE 9 LP	 	CITRINE BIOTECH 10 LP

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]